Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period

BACKGROUND: Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Hyuk, Kim, Yong Soo, Chung, Wookyung, Kim, Yong Lim, Kim, Yaerim, Han, Seungyeup, Jung, Yeonsoon, Na, Ki Young, Lee, Kyu Beck, Oh, Yun Kyu, Park, Hyeong Cheon, Han, Seung Hyeok, Yoo, Tae Hyun, Kim, Yeong Hoon, Kim, Soo Wan, Lee, Kang Wook, Park, Hayne Cho, Kim, Sung Gyun, Kim, Hyunsuk, Lee, Chang Hwa, Bae, Kyongtae T., Oh, Kook Hwan, Ahn, Curie, Ryu, Hyun Jin, Kim, Yong Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Nephrology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085719/
https://www.ncbi.nlm.nih.gov/pubmed/36634967
http://dx.doi.org/10.23876/j.krcp.22.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085719/
https://www.ncbi.nlm.nih.gov/pubmed/36634967
http://dx.doi.org/10.23876/j.krcp.22.024

Ejemplares similares